title: Management of superficial transitional cell carcinoma of the bladder.
abstract: Intravesical therapy for the treatment of existing bladder cancer or for prophylaxis of recurrent disease should be chosen according to the stage of transitional-cell cancer. Papillary disease (stages Ta, T1) may be treated effectively with either an alkylating agent or with BCG. BCG is the agent of choice for the treatment of Tis, provided that the treatment course includes 12 weekly and 12 monthly instillations.
authors.affiliation: Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY.
authors.forename: J
authors.initials: J
authors.lastname: Fleischmann
authors.forename: G
authors.initials: G
authors.lastname: Goldberg
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D053685:Laser Therapy; D010778:Photochemotherapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine